Clinical Trials Logo

Clinical Trial Summary

Previous work performed by University of New Mexico Comprehensive Cancer Center (UNMCCC) investigators has revealed previously unknown genomic mutations in children, adolescents, and young adults with high-risk B and T cell precursor acute lymphoblastic leukemia (ALL). Using genomic and next generation DNA sequencing technologies, these investigators revealed that 14% of children with high-risk ALL have "Philadelphia chromosome-like" ("Ph-like") ALL. Patients with this form of ALL were found to have a significantly increased risk of treatment failure and death. Further work revealed that there are more than 40 distinct gene rearrangements and fusions that can result in Ph-like ALL. Cell lines and human leukemic cells expressing some of these different gene fusions were sensitive to currently available drugs. This suggests that Ph-like ALL patients with these specific distinct gene fusions should be targeted in future clinical trials to be treated with appropriate therapy. Further work is also needed to identify other potentially targetable genetic alterations in ALL patients. Therefore, the goal of this study is to perform genomic screening of all newly diagnosed ALL patients seen at UNM and to use this information to enroll patients onto available National Clinical Trial Network (NCTN) clinical trials. If an appropriate NCTN trial is not available, best clinical management will be pursued.


Clinical Trial Description

The work performed by UNMCCC investigators and others as described briefly above has provided major insights into the biologic and clinical features and the genomic landscape of Ph-like ALL, which is strikingly heterogeneous. Gene expression profiling and RNA/transcriptomic, exome, and whole genome sequencing have identified several distinct subclasses of kinase activating lesions in 91% of the Ph-like ALL cases studied to date, most commonly kinase and cytokine receptor gene rearrangements and fusions. UNMCCC investigators are now collaborating with Children's Oncology Group (COG) and the adult National Cancer Institute (NCI) Cooperative Groups (Southwest Oncology Group (SWOG), Eastern Cooperative Oncology Group (ECOG) - American College of Radiology Imaging Network (ACRIN), The Alliance) to develop national clinical trials for pediatric, adolescent and young adult (AYA), and adult ALL patients that incorporate their genomic diagnostic screens, molecular diagnostics, and next generation sequencing studies to identify underlying genomic lesions in ALL and target patients to appropriate therapeutic regimens. In this feasibility study, next generation sequencing (NGS) technologies will inform an acute lymphoblastic leukemia risk classification system, which may be adapted to identify patients who might benefit from targeted therapies; such patients will be targeted to NCTN National Treatment trials or UNMCCC-sponsored trials where appropriate, through detailed genomic data analysis performed under College of American Pathologists (CAP)/CLIA conditions and in individual case discussions in a Molecular Tumor Board. In addition, the association of race and ethnicity with the spectrum of ALL-associated genomic mutations in the New Mexico and regional ALL population, which includes a significant proportion of underrepresented minorities, will be studied. This may ultimately allow for the development of an ancestry-based risk classification system. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02580981
Study type Interventional
Source New Mexico Cancer Care Alliance
Contact
Status Terminated
Phase N/A
Start date July 28, 2016
Completion date October 20, 2022

See also
  Status Clinical Trial Phase
Unknown status NCT02360930 - Vincristine PK and PD in the AYA Population Compared to Younger Children N/A
Recruiting NCT05306301 - Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients Phase 2
Not yet recruiting NCT06101381 - CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma Phase 1/Phase 2
Terminated NCT02935543 - CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL Phase 2
Active, not recruiting NCT05440409 - CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL
Completed NCT02393859 - Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) Phase 3
Completed NCT05064787 - Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy N/A
Terminated NCT02435550 - iCare for Cancer Patients N/A
Completed NCT02799147 - GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia Phase 1/Phase 2
Recruiting NCT04307576 - A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Phase 3
Completed NCT04942730 - Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) Phase 2
Terminated NCT01761682 - Acute Lymphoblastic Leukemia Registry at Asan Medical Center
Completed NCT04327037 - Safety of Expanded Haploidentical Natural Killer Cells for Leukemia Phase 1
Terminated NCT02349178 - Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT Phase 2
Recruiting NCT04209244 - Effect of Fish Oil on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia N/A
Recruiting NCT03911128 - A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
No longer available NCT00590915 - Erwinase Master Treatment Protocol N/A